Pharma BD Deal Intelligence
A $200M bispecific antibody research partnership, not an acquisition, that yielded one discontinued program and one returned asset before Incyte exited its Merus equity stake for a $106M gain in 2024 — a modest financial win overshadowed by Genmab's subsequent $8B buyout of Merus, an upside Incyte never captured.
Not an acquisition at all: Incyte never bought Merus — it was a $200M bispecific research partnership that produced one discontinued asset (INCA32459), a returned program (MCLA-145), and a profitable but modest equity exit ($216M/$106M gain) before Merus was acquired independently by Genmab for $8B in 2025.
Full analysis, sources & comparables →BioPharma Dive framed the transaction as Incyte addressing a pipeline gap by tapping Merus's Biclonics platform across up to 11 programs, with milestones up to…
GEN's coverage was favorable, citing Incyte CSO comments that bispecific antibodies 'have the potential to play an important role in the future of…
A Seeking Alpha contributor rated Merus 'a speculative buy as there are several important catalysts this year in addition to several candidates entering the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Incyte and Merus closed a global strategic research collaboration to discover, develop and commercialize up to 11 bispecific antibodies across oncology. Merus received a $120M upfront cash payment plus an $80M equity investment ($200M total at closing) and is eligible for up to $350M per program in development, regulatory and sales milestones (~$2.8B aggregate across remaining programs) plus tiered royalties. Original deal announced December 21, 2016 with closing in January 2017.
Not an acquisition at all: Incyte never bought Merus — it was a $200M bispecific research partnership that produced one discontinued asset (INCA32459), a returned program (MCLA-145), and a profitable but modest equity exit ($216M/$106M gain) before Merus was acquired independently by Genmab for $8B in 2025.
Assessment window: 5yr post-close.
The collaboration spanned multiple solid-tumor indications via Merus's Biclonics bispecific antibody platform rather than a single disease. Bispecific antibodies bridge two targets simultaneously — typically a tumor antigen plus an immune effector or co-receptor — to drive tumor-selective killing or block resistance pathways that monospecifics cannot.
At deal close, the bispecific antibody field was crowded but largely pre-clinical outside of Amgen's Blincyto (blinatumomab, BiTE for B-ALL) and Roche's Hemlibra (emicizumab, hemophilia). Multiple platforms were competing for big-pharma attention: Xencor's XmAb, MacroGenics's DART, Zymeworks's Azymetric/EFECT, Affimed's ROCK platform, and Genmab's DuoBody (which Janssen used for Rybrevant/amivantamab). Merus's Biclonics differentiator was a common light-chain architecture that enables full-length IgG-like manufacturing without complex engineering. The Incyte deal — $200M at closing plus up to $2.8B in milestones across up to 11 programs — represented one of the larger early-stage bispecific platform transactions of the cycle and validated the platform alongside earlier J&J, Pfizer and Novartis tie-ups. For Incyte, the deal addressed a pipeline gap beyond Jakafi/ruxolitinib and the IDO-1 program (epacadostat), giving it an oncology bispecific franchise without internal antibody discovery infrastructure. Merus retained its lead clinical assets MCLA-128 (zenocutuzumab, NRG1 fusion tumors, later Bizengri) and MCLA-117.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Incyte Corporation / Merus N.V. (this deal) | 2017 | $3.0B | 35 |
| Incyte Corporation / MacroGenics, Inc. | 2017 | $900M | 69 |
| Incyte Corporation / Vega Therapeutics, Inc. | 2026 | $2.0B | 68 |
| Incyte Corporation / Halozyme Therapeutics, Inc. | 2026 | — | 60 |
| Incyte Corporation / Genesis Molecular AI, Inc. | 2026 | $1.0B | — |
| Incyte Corporation / Escient Pharmaceuticals Inc. | 2024 | $750M | — |
| Incyte Corporation / Calithera Biosciences, Inc. | 2017 | $803M | — |
← Browse all deals · How we score deals
More: 2017 deals · Incyte Corporation deals · Oncology deals